The American Association for Cancer Research (AACR) has announced the appointment of Elizabeth M. Jaffee and Antoni Ribas as Editors-in-Chief of Cancer Immunology Research, one of the association’s peer-reviewed journals focused on advances in cancer immunology and immunotherapy.
Cancer Immunology Research publishes original research spanning basic, translational, and clinical studies, including investigations into host–tumor interactions, developmental therapeutics, early-stage patient research, and late-stage clinical trials. The journal serves a multidisciplinary research community and disseminates findings intended to improve clinical outcomes in cancer care.
Under the new editorial leadership, the journal will continue to emphasize scientific rigor, reproducibility, and collaboration across disciplines. The editors have outlined a vision that includes highlighting data-intensive research, computational biology, systems immunology, and advanced technologies used to study patient samples, treatment response, and resistance mechanisms.
Jaffee brings extensive experience in cancer immunology research, academic leadership, and scholarly publishing. She has served in senior editorial roles across multiple AACR journals and has held leadership positions within the AACR, including prior service as president and as a member of the board of directors. Her research has contributed to the development and clinical evaluation of immunotherapies, particularly in pancreatic cancer.
Ribas is a physician-scientist recognized for contributions to melanoma research and immunotherapy development. His work has played a role in advancing anti-PD-1 therapies and in elucidating molecular mechanisms of immunotherapeutic resistance. Ribas has also served in editorial and leadership roles within AACR, including as past president of the association.
Both editors have published an editorial in the current issue of Cancer Immunology Research outlining priorities for the journal. The AACR has indicated that their combined expertise is expected to strengthen the journal’s role in advancing cancer immunology research within the broader scholarly publishing landscape.
Click here to read the original press release.
